Related Experiment Video
Updated: May 28, 2026
08:17
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
Temporary gastric neuromodulation for intractable nausea and vomiting.
S Ullah1, R Arsalani-Zadeh, P Sedman
1Academic Surgical Unit, Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire HU16 5JQ, UK. drsanavri@hotmail.com
Annals of the Royal College of Surgeons of England
|November 2, 2011
Summary
Gastric neuromodulation (GNM) improved symptoms and quality of life in patients with severe nausea and vomiting. This treatment also led to weight gain and better gastric emptying in a small study group.
Area of Science:
- Gastroenterology
- Medical Devices
- Neuromodulation
Background:
- Gastric neuromodulation (GNM) is proposed for drug-refractory gastroparesis and persistent nausea/vomiting.
- Objective data on GNM efficacy, especially gastric emptying, is limited.
Purpose of the Study:
- To evaluate the effects of GNM on upper gastrointestinal symptoms, gastric emptying, and quality of life.
- To assess GNM's impact on nutritional status and weight in patients with intractable nausea and vomiting.
Main Methods:
- Six patients with gastroparesis or nausea/vomiting underwent endoscopic GNM for seven days.
- Gastric scintigraphy, symptom scores (TSS, VFS), SF-12 quality of life, and nutritional status were assessed before and after GNM.
Main Results:
- Total gastroparesis symptom scores (TSS) and vomiting frequency scores (VFS) improved.
- Quality of life (SF-12 physical and mental scores) and oral intake improved.
- Significant weight gain (mean 1kg) and improved gastric emptying half-time were observed in most patients.
Conclusions:
- GNM shows promise in alleviating upper gastrointestinal symptoms, enhancing quality of life, and improving nutritional status.
- GNM warrants further investigation as a therapeutic option for intractable nausea and vomiting.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:22Pathophysiology of Vomiting
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through interaction...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:16Gastric Motility
Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...